News
2021 Updates: Lilly's Global COVID-19 Response
View Story
Supporting United Way to Meet New Challenges
View Story
Racial Justice Initiative: Confronting Racial Inequities Head On
View Story
How Digital and Remote Health Can Help Next-Generation VBAs
View Story
Meet the Women Behind Our Cancer Research
View Story
Christalyn Rhodes: Living Her Purpose, Our Purpose
View Story
February 26, 2021
Tags | Product
INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received
February 25, 2021
Tags | Product
COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly 's connected insulin solutions, currently in development.
INDIANAPOLIS , Feb. 24, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41 st Annual Health Care Conference on Thursday, March 4, 2021 . Daniel Skovronsky , M.D., Ph.D., Lilly 's Chief Scientific Officer and President of Lilly Research Laboratories
February 18, 2021
Tags | Corporate
- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications - Rigel will receive an upfront cash payment of $125 million, with the potential for up to an additional $835 million in future development, regulatory,